TTF-1 in extra-pulmonary adenocarcinoma (excluding thyroid neoplasms)

Breast	0/141 (0/965, 0/1815, 0/5 (signet ring cell carcinomas)19, 0/7 (metastases to brain)23, 0/534, 0/10(using monoclonal 8G7G3/1)6), 0/13(using clone 8G7G3/1)7, 0/8(cell blocks from cases with metastatic adenocarcinoma to serous cavities, using clone 8G7G3/1)9, 0/51(using a polyclonal antibody)1, 0/2(lung metastasis, using clone 8G7G3/1)8, 0/25(using clone 8G7G3/1)35
Salivary gland	0/3 (metastases to brain)23
Oesophagus	0/315
Stomach	1/98 (1/661, 0/315, 0/519, 0/2431), 0/2(using clone 8G7G3/1)7, 0/9(cell blocks from cases with metastatic adenocarcinoma to serous cavities, using clone 8G7G3/1)9
Colon	0/230 (0/18 (primary tumours, using polyclonal antibody)1, 0/21 (primary tumours, using clone8G7G3/1)2, 0/30(primary tumours, using clone8G7G3/1)4 , 0/20(primary tumours, using clone 8G7G3/1)6, 0/26(primary tumours, using clone 8G7G3/1)7, 0/3(lung metastasis, using clone 8G7G3/1)8, 0/8(cell blocks from cases of metastatic carcinoma to serous cavities, using clone 8G7G3/1)9, 0/6(lung metastasis, using clone 8G7G3/1)10, 0/5(lung metastasis, using clone 8G7G3/1)11, 0/26(lung metastasis, using clone 8G7G3/1)12, 0/519, 0/1(metastases to brain)23, 0/3531, 0/1634), 0/10(using clone 8G7G3/1)35
Liver	0/22(using monoclonal 8G7G3/1)6, 0/2(lung metastasis, using clone 8G7G3/1)8
Gallblader	0/115
Pancreas	0/9 (0/215, 0/731)
Kidney	0/41 (0/185, 0/14 (metastases to brain)23, 0/934), 0/7(using clone 8G7G3/1)7, 0/8(using a polyclonal antibody)1, 0/2(lung metastasis, using clone 8G7G3/1)8, 0/10(using clone 8G7G3/1)35
Ovary	0/305, 1/16 (few very weakly reactive cells)15, 0/1531, 15/53 (endometrioid: 3/8, serous: 6/25; strong in one case, clear cell: 4/10; strong in two cases, mucinous: 2/10; strong in one case)33, 0/234, 0/15(cell blocks from cases with metastatic adenocarcinoma to serous cavities, using clone 8G7G3/1)9, 0/4(lung metastasis, using clone 8G7G3/1)8, 0/30(using clone 8G7G3/1)35, 2/166 (strong nuclear staining in one mixed serous and endometrioid carcinoma and one serous carcinoma: in the latter, staining was confined to poorly differentiated areas. The other 50 serous, 30 endometrioid, 23 mucinous, 30 clear cell, 24 mixed epithelial, and 7 mixed mixed Mullerian tumours were all negative. Staining was done using clone 8G7G3/1)36
Endometrium	1/40 (1/81, 0/415, 0/2531, 0/334), 0/1(using monoclonal 8G7G3/1)6, 0/6(lung metastasis, using clone 8G7G3/1)8
Prostate	0/21 (0/195, 0/215), 0/9(using a polyclonal antibody)1, 0/1(lung metastasis, using clone 8G7G3/1)8, 0/10(using clone 8G7G3/1)35
Total	18/534 (2/2865, 1/4915, 0/1519, 0/2523, 0/10631, 15/5333)

¹⁵†using cell blocks from FNAs

I have seen one focally positive colorectal metastasis to lung., unpublished case.

References

¹ Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 1996; 9:445-52

²Holzinger A, Dingle S, Bejarano PA, et al. Monoclonal antibody to thyroid transcription factor-1: production, characterization, and usefulness in tumor diagnosis. Hybridoma 1996; 15:49-53

³ Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol 2000; 24:1217-23

⁴ Kaufmann O,Dietel M Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000; 36:8-16

⁵ Ordonez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Advances in Anatomic Pathology 2000; 7(2): 123-127.

⁶ Chang YL, Lee YC, Liao WY, et al. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer 2004; 44:149-57

⁷ Moldvay J, Jackel M, Bogos K, et al. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res 2004; 10:85-8

⁸ Reis-Filho JS, Carrilho C, Valenti C, et al. Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lung adenocarcinomas? Pathol Res Pract 2000; 196:835-40

⁹ Jang KY, Kang MJ, Lee DG, et al. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Anal Quant Cytol Histol 2001; 23:400-4

¹⁰ Chhieng DC, Cangiarella JF, Zakowski MF, et al. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer 2001; 93:330-6

¹¹ Ng WK, Chow JC,Ng PK Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens. Cancer 2002; 96:43-8

¹² Wieczorek TJ, Pinkus JL, Glickman JN, et al. Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. Am J Clin Pathol 2002; 118:911-21

¹⁵ Hecht, J. L., Pinkus, J. L., Weinstein, L. J., Pinkus, G. S. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin Am J Clin Pathol 2001;116:483-488.

¹⁹ Merchant, S.H., Amin, M.B., Tamboli, P., Ro, J., Ordonez, N.G., Ayala, A.G., Czerniak, B.A. and Ro, J.Y. Primary signet-ring cell carcinoma of lung: immunohistochemical study and comparison with non-pulmonary signet-ring cell carcinomas. Am J Surg Pathol 2001;25:1515-9.

²³ Srodon, M. and Westra, W.H. Immunohistochemical staining for thyroid transcription factor-1: a helpful aid in discerning primary site of tumor origin in patients with brain metastases. Hum Pathol 2002;33:642-5.

³¹ Stenhouse, G., N. Fyfe, et al. (2004). "Thyroid transcription factor 1 in pulmonary adenocarcinoma." J Clin Pathol 57(4): 383-7.

³³ Quddus MR et al. Expression of TTF-1 in primary ovarian surface epithelial carcinomas: a study of 53 cases. Modern Pathology 2004 17(1):211A.

³⁴ Jerome Marson, V., J. Mazieres, et al. (2004). "Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade." Histopathology 45(2): 125-34.

³⁵ Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000; 24:598-606.

³⁶ Histopathology 2006;48:764.

This page last revised9.5.2006.

©SMUHT/PW Bishop